CGEMCullinan Therapeutics, Inc.

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Cullinan Therapeutics reported second-quarter 2026 results with a net loss of US$53.7 million and basic loss per share of US$0.81, both lower than a year earlier, alongside six-month net loss of US$103.37 million. The company also received positive U.S. FDA feedback that supports launching a potentially registrational Phase 2 trial for its FLT3xCD3 engager CLN-049 in relapsed/refractory acute myeloid leukemia, marking a key clinical and regulatory step for its lead program. We’ll now examine...

Cullinan Therapeutics (CGEM) drew investor attention after receiving positive U.S. Food and Drug Administration feedback on its End of Phase 1 meeting for CLN-049 in acute myeloid leukemia. See our latest analysis for Cullinan Therapeutics. Against this backdrop, Cullinan Therapeutics’ share price has eased in the very short term, with a 1-day share price return of 1.49% lower and a 7-day return of 2.49% lower. However, the 90-day share price return of 31.88% and year to date share price...